TRex Bio
Ariella Kelman currently serves as Chief Medical Officer at TRexBio, a position held since March 2025, following a tenure in the same role at Biora Therapeutics from May 2023 to April 2025. Prior to these roles, Ariella was Senior Vice President of Clinical Development at HIBio from November 2021 to May 2023, and spent nearly nine years at Genentech, where responsibilities included Senior Group Medical Director and Global Head of Bioethics, as well as roles in Clinical Development for Immunology. In addition to industry experience, Ariella served as an Adjunct Associate Clinical Professor and Attending Physician at Stanford University School of Medicine from October 2005 to June 2015. Educational qualifications include a Graduate Professional Certificate in Bioethics from Columbia University and a Fellowship in Immunology and Rheumatology from Stanford University School of Medicine.
This person is not in any teams
This person is not in any offices
TRex Bio
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases.